ALT / Altimmune's Peptide-Based Therapies Offer Substantial Opportunity

Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, unde more_horizontal

GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that n more_horizontal

Altimmune's stock has disappointed shareholders over the past year, with disappointing trial results triggering a significant drop in equity in March more_horizontal

Penny stocks, typically defined as stocks trading under $5 per share, offer traders massive upside profit potential but also higher risk due to greate more_horizontal

Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line more_horizontal

GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that m more_horizontal

GAITHERSBURG, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that i more_horizontal

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% more_horizontal